For years, the connected body has been blocked by physics. Bluetooth and NFC signals die quickly in human tissue. Antennas must be large enough to function, power budgets are brutal, and implants are often too big to inject without surgery. The result is a fragmented body, each device an island. As reported by TechXplore, the human body is 'terrible' at allowing traditional wireless signals to pass through, and those signals require large antennas and lots of power.
But the body is not a neutral wire. It is a shared medium, and the first company to own the protocol will own the network inside every patient.
On September 24, 2026, Georgia Tech engineers published a paper in the journal Science describing a wireless networking system called SWANS, for Smart Wireless Autonomous Networking System. Small implantable sensors and actuators can communicate with each other and with wearable devices using the human body as the transmission medium. The devices send signals through surrounding tissue without wires, alignment, or proximity. Senior author Alex Abramson, an assistant professor in the School of Chemical and Biomolecular Engineering, said the goal was to imitate the connectedness the body achieves through its own nervous system.
The system allows devices small enough to be implanted via syringe instead of surgery, according to the Georgia Tech College of Engineering.
Body network implants: how SWANS uses the body to transmit signals
The mechanism is straightforward to state and difficult to build. Instead of fighting tissue, SWANS uses tissue as the transmission medium. Devices send signals through the surrounding tissue, removing the size and power constraints that Bluetooth and NFC impose. This unlocks a new design space. A sensor can sit where it most accurately detects a biological signal, and an actuator can sit where it most effectively performs a therapeutic action. They do not need to be near each other or even aligned.
Abramson put it directly in the Georgia Tech announcement: 'With our system, you can now place sensors in the best possible place to detect a biological signal and place actuators in the best possible place to perform a therapeutic action. They don't need to be connected, aligned, or even near each other; they can just send signals to each other through the surrounding tissue.'
The communication method is expandable to include multiple interconnected devices across the body, even deep inside the stomach. Lead study author Ramy Ghanim and co-author Joy Jackson tested a small implantable device alongside Abramson.
What is not yet known matters as much as what is. The published research does not specify range, data rate, power consumption, security, or a regulatory path. No human trials have been announced. No commercial partner has been named. The scientific claim is strong. The infrastructure question is silent.
The evidence is strong on the claim, silent on the protocol
What is confirmed: the Georgia Tech College of Engineering news release, published Thursday, 24 September 2026, describes the system, quotes Abramson, and names Ghanim and Jackson. The paper is in Science. The system allows sensing in one part of the body and triggering a therapeutic response elsewhere, such as releasing medicine or stimulating a nerve.
What is reported by TechXplore: the name SWANS, the syringe-injectable size, the limits of Bluetooth and NFC. The system removes the need for large antennas and lots of power.
What is not known: the security model, the data rate, the power source, the protocol. That silence is the story.
The protocol, not the device, is the prize
The consensus will treat SWANS as a clever engineering fix for a physical limitation. That misses the point. The real breakthrough is not that signals pass through tissue. It is that the body becomes a shared medium, which means every implant is potentially a node on a network that someone else controls.
Here is the chain. First, the mechanism: SWANS proves the body can be a network medium. Second, what it forces next: once implants can talk to each other, they need a protocol. Addressing, routing, security, authentication. The body becomes a local area network. Third, the second-order consequence: the company that owns the protocol owns the data pipeline from inside the patient. Device makers become commodity hardware vendors. The protocol owner captures the recurring revenue, the data, and the regulatory moat.
Fourth, the third-order consequence: a consortium forms around a body-area networking standard. The leading candidates to lead it are Apple or Google, because they already own the wearable layer and the health data platform. Medical device companies, such as Medtronic, Abbott, and Boston Scientific, will be forced to either join or acquire. Within 12 to 24 months, at least one major medical device company will acquire or partner with a body-as-network startup. The FDA will begin drafting guidance for intrabody communication standards, because the security and privacy implications are too large to ignore.
The battle will not be over sensor accuracy or battery life. The device on your wrist is a peripheral. The network inside your body is the platform.
The security and privacy implications are unaddressed in the published research. If the body is a network, then the network can be hacked, monitored, or shut down by whoever owns the infrastructure. This is a new attack surface inside the human body.
What changes for patients, clinicians, and device makers
For patients, the promise is a body that heals itself in a coordinated way. A sensor detects a biomarker, an actuator releases a drug, a nerve is stimulated. But the same network that enables therapy enables surveillance. The data pipeline from inside the body is the most intimate data stream ever created.
For clinicians, the shift is from managing a device to managing a network. A broken node is not a failed implant but a loss of connectivity in a system.
For device makers, the choice is to become a node on someone else's network or build their own. The economics of owning a protocol versus selling a device are not close.
For regulators, the FDA will have to regulate a protocol, not just a product. That is a different kind of oversight, and it has not started.
The body-as-network is a new site of power. The question is not whether it will happen, but who will own it.
The body is the network
A body network once meant a set of devices that could not talk to each other. Now, Georgia Tech has shown that the body itself can be the medium. The first company to own the protocol will own the network inside every patient.
The device on your wrist is a peripheral. The network inside your body is the platform.
